瑞普生物
(300119)
| 流通市值：72.52亿 | | | 总市值：100.62亿 |
| 流通股本：3.35亿 | | | 总股本：4.65亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,707,587,656.8 | 821,616,475.9 | 3,069,933,116.78 | 1,746,806,365.21 |
| 营业收入 | 1,707,587,656.8 | 821,616,475.9 | 3,069,933,116.78 | 1,746,806,365.21 |
| 二、营业总成本 | 1,464,234,653.83 | 694,874,920.33 | 2,690,140,421.73 | 1,466,821,630.31 |
| 营业成本 | 989,391,177.59 | 482,898,269.73 | 1,799,722,621.6 | 884,008,727.7 |
| 税金及附加 | 13,987,702.16 | 5,832,045.84 | 26,346,455.03 | 16,770,627.63 |
| 销售费用 | 235,038,147.08 | 100,376,582.8 | 451,383,069.54 | 287,789,963.33 |
| 管理费用 | 103,829,285.28 | 49,054,825.1 | 188,944,340.45 | 124,969,273.64 |
| 研发费用 | 104,020,978.37 | 47,940,755.91 | 196,537,745.61 | 135,162,744.28 |
| 财务费用 | 17,967,363.35 | 8,772,440.95 | 27,206,189.5 | 18,120,293.73 |
| 其中:利息费用 | 18,361,731.74 | 9,181,009.35 | 31,214,673.37 | 21,717,594.87 |
| 其中:利息收入 | 1,252,878.73 | 625,210.59 | 4,969,935.23 | 3,798,131.31 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 43,282,384.88 | 25,328,670.23 | -10,707,752.8 | 23,485,986.01 |
| 加:投资收益 | 32,094,818.1 | -701,082.24 | 9,142,829.12 | 1,580,137.03 |
| 资产处置收益 | 3,729,955.17 | 1,061.15 | -16,698.12 | 8,426.89 |
| 资产减值损失(新) | 373,473.73 | 373,473.73 | -19,849,519.54 | 382,169.91 |
| 信用减值损失(新) | -20,748,539.02 | -19,476,374.62 | -19,456,021.42 | -18,427,216.54 |
| 其他收益 | 10,040,094.62 | 5,073,106.48 | 34,262,426.62 | 17,064,992.56 |
| 四、营业利润 | 312,125,190.45 | 137,340,410.3 | 373,167,958.91 | 304,079,230.76 |
| 加:营业外收入 | 1,961,830.86 | 221,917.66 | 1,598,005.56 | 1,305,761.7 |
| 减:营业外支出 | 2,577,767.85 | 2,130,159.16 | 6,476,839.56 | 3,096,113.45 |
| 五、利润总额 | 311,509,253.46 | 135,432,168.8 | 368,289,124.91 | 302,288,879.01 |
| 减:所得税费用 | 39,445,666.57 | 15,327,402.5 | 38,455,221.73 | 38,106,138.18 |
| 六、净利润 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 256,522,468.88 | 115,984,657.96 | 300,722,269.32 | 244,736,518.03 |
| 少数股东损益 | 15,541,118.01 | 4,120,108.34 | 29,111,633.86 | 19,446,222.8 |
| 扣除非经常损益后的净利润 | 187,741,091.62 | 93,461,027.11 | 280,620,866.2 | 214,051,835.51 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.56 | 0.25 | 0.65 | 0.53 |
| (二)稀释每股收益 | 0.56 | 0.25 | 0.65 | 0.53 |
| 九、综合收益总额 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 |
| 归属于母公司股东的综合收益总额 | 256,522,468.88 | 115,984,657.96 | 300,722,269.32 | 244,736,518.03 |
| 归属于少数股东的综合收益总额 | 15,541,118.01 | 4,120,108.34 | 29,111,633.86 | 19,446,222.8 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-04-03 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |